Impact of Variations in Test Method Parameters on in Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing

Journal of Clinical Microbiology

Volumn 54, Issue 3, 2016, Pages 749-753

  Traczewski, Maria M ^a   Deane, Jennifer ^b,d   Sahm, Daniel ^b,e   Brown, Steven D ^a   Chesnel, Laurent ^c  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b Eurofins Medinet Inc   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ATCC   (United States)

^e International Health Management Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CLINDAMYCIN; LIPOPEPTIDE; SUROTOMYCIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; EGGERTHELLA LENTA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; QUALITY CONTROL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84959533473     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02881-15     Document Type: Article

References (26)

1. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09.
2. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55(Suppl 2):S65-S70. http://dx.doi.org/10.1093/cid/cis319.
3. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. 2012. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther 10:1405-1423. http://dx.doi.org/10.1586/eri.12.135.
4. Jones AM, Kuijper EJ, Wilcox MH. 2013. Clostridium difficile: A Euro-pean perspective. J Infect 66:115-128. http://dx.doi.org/10.1016/j.jinf .2012.10.019.
5. Eggertson L. 2005. C. difficile may have killed 2000 in Quebec: Study. CMAJ 173:1020-1021. http://dx.doi.org/10.1503/cmaj.051226.
6. Zilberberg MD, Shorr AF, Kollef MH. 2008. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 14:929-931. http://dx.doi.org/10.3201/eid1406.071447.
7. Redelings MD, Sorvillo F, Mascola L. 2007. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 13:1417-1419. http://dx.doi.org/10.3201/eid1309.061116.
8. Mitchell BG, Gardner A. 2012. Mortality and Clostridium difficile infection: A review. Antimicrob Resist Infect Control 1:20. http://dx.doi.org/10.1186/2047-2994-1-20.
9. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. 2014. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin Infect Dis 59:345-354. http://dx.doi.org/10.1093/cid/ciu313.
10. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. 2007. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.Am J Gastroenterol 102:2781-2788. http://dx.doi.org/10.1111/j.1572-0241 .2007.01539.x.
11. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586-1590. http://dx.doi.org/10.1086/430311.
12. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
13. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281-289. http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
14. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
15. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613-1615. http://dx.doi.org/10.1128/AAC.05655-11.
16. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448-3452. http://dx.doi.org/10.1128/AAC .06257-11.
17. Mascio CT, Chesnel L, Thorne G, Silverman JA. 2014. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58:3976-3982. http://dx.doi.org/10.1128/AAC.00124-14.
18. Bouillaut L, McBride S, Sorg JA, Scmidt D, Suarez J, Chesnel L, Sonenshein AL. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr C-164.
19. Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr C-170.
20. Cannon K, Byrne B, Happe J, Louie T. 2012. Abstr 22nd Eur Congr Clin Microbiol Infect Dis, abstr 2250.
21. Citron DM, Goldstein EJC. 2011. Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. Diagn Microbiol Infect Dis 70:554-556. http://dx.doi.org/10.1016/j.diagmicrobio.2011.04.012.
22. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard- 7th ed. CLSI document M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Barry AL, Fuchs PC, Brown SD. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45:1919-1922. http://dx.doi.org/10.1128/AAC.45.6.1919-1922.2001.
24. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline-3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob Agents Chemother 51: 2483-2488. http://dx.doi.org/10.1128/AAC.01457-06.